Balchem (NASDAQ:BCPC - Get Free Report) is set to post its quarterly earnings results before the market opens on Friday, October 25th. Analysts expect Balchem to post earnings of $1.03 per share for the quarter. Individual interested in participating in the company's earnings conference call can do so using this link.
Balchem (NASDAQ:BCPC - Get Free Report) last issued its earnings results on Friday, July 26th. The basic materials company reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.03. Balchem had a return on equity of 10.94% and a net margin of 12.52%. The business had revenue of $234.08 million during the quarter, compared to analyst estimates of $241.26 million. On average, analysts expect Balchem to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Balchem Stock Down 0.9 %
BCPC traded down $1.48 during midday trading on Friday, reaching $170.55. 86,382 shares of the company were exchanged, compared to its average volume of 106,494. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The company's fifty day moving average price is $171.26 and its 200 day moving average price is $161.54. The company has a market cap of $5.53 billion, a price-to-earnings ratio of 48.18, a price-to-earnings-growth ratio of 5.43 and a beta of 0.65. Balchem has a one year low of $110.74 and a one year high of $186.03.
Insiders Place Their Bets
In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the business's stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the transaction, the senior vice president now owns 8,540 shares in the company, valued at $1,537,627. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 1.25% of the company's stock.
Analysts Set New Price Targets
A number of brokerages have commented on BCPC. StockNews.com lowered Balchem from a "buy" rating to a "hold" rating in a report on Monday, July 29th. HC Wainwright boosted their price objective on Balchem from $170.00 to $185.00 and gave the stock a "buy" rating in a report on Wednesday, July 31st.
Read Our Latest Research Report on Balchem
Balchem Company Profile
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Further Reading
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
